These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Neuroleptic-induced catatonia: neuroleptic malignant syndrome? de Leon J; Saiz-Ruiz J; Alonso-Abolafia A; Pico-Soler E; Munoz-Ruata J; de la Serna I Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):129-36. PubMed ID: 1967846 [TBL] [Abstract][Full Text] [Related]
27. Detection and management of the neuroleptic malignant syndrome. Bond WS Clin Pharm; 1984; 3(3):302-7. PubMed ID: 6145537 [TBL] [Abstract][Full Text] [Related]
28. Psychiatric Emergencies for Clinicians: Emergency Department Management of Neuroleptic Malignant Syndrome. Wilson MP; Vilke GM; Hayden SR; Nordstrom K J Emerg Med; 2016 Jul; 51(1):66-9. PubMed ID: 27247083 [No Abstract] [Full Text] [Related]
29. A protocol for the diagnosis and treatment of extrapyramidal symptoms of neuroleptic drugs. Bickal T Nurse Pract; 1987 Jan; 12(1):25, 29, 32 passim. PubMed ID: 2880325 [TBL] [Abstract][Full Text] [Related]
30. [Neuroleptic malignant syndrome and related conditions]. Amore M; Montanari M Minerva Psichiatr; 1992; 33(4):259-83. PubMed ID: 1363674 [TBL] [Abstract][Full Text] [Related]
31. Catatonia and malignant syndrome: a possible complication of neuroleptic administration. Report of a case involving haloperidol. Weinberger DR; Kelly MJ J Nerv Ment Dis; 1977 Oct; 165(4):263-8. PubMed ID: 908924 [TBL] [Abstract][Full Text] [Related]
32. Catatonic Symptoms Appearing before Autonomic Symptoms Help Distinguish Neuroleptic Malignant Syndrome from Malignant Catatonia. Komatsu T; Nomura T; Takami H; Sakamoto S; Mizuno K; Sekii H; Hatta K; Sugita M Intern Med; 2016; 55(19):2893-2897. PubMed ID: 27725556 [TBL] [Abstract][Full Text] [Related]
33. Residual catatonic state following neuroleptic malignant syndrome. Caroff SN; Mann SC; Keck PE; Francis A J Clin Psychopharmacol; 2000 Apr; 20(2):257-9. PubMed ID: 10770467 [TBL] [Abstract][Full Text] [Related]
34. Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. Harsch HH J Clin Psychiatry; 1987 Aug; 48(8):328-33. PubMed ID: 2886491 [TBL] [Abstract][Full Text] [Related]
36. Functional hyperthermia due to central dopaminergic impairment. Di Rosa AE; Morgante L; Coraci MA; Crisafulli A; Cacciola G; Di Stefano G; Meduri M; Di Perri R Funct Neurol; 1988; 3(2):211-5. PubMed ID: 2900182 [TBL] [Abstract][Full Text] [Related]
37. [Differential diagnosis of acute life threatening catatonia and malignant neuroleptic syndrome--a case report]. Hermle L; Oepen G Fortschr Neurol Psychiatr; 1986 Jun; 54(6):189-95. PubMed ID: 2873091 [TBL] [Abstract][Full Text] [Related]
38. [Neuroleptic malignant syndrome in users of risperidone]. Gerritsen AA; de Jonghe-Rouleau AP; Stienstra-Liem LH Ned Tijdschr Geneeskd; 2004 Sep; 148(37):1801-4. PubMed ID: 15495506 [TBL] [Abstract][Full Text] [Related]
39. [Neuroleptic malignant syndrome : Rare cause of fever of unknown origin]. Chackupurakal R; Wild U; Kamm M; Wappler F; Reske D; Sakka SG Anaesthesist; 2015 Jul; 64(7):527-31. PubMed ID: 26122200 [TBL] [Abstract][Full Text] [Related]
40. Rhabdomyolysis and hyperthermia after cocaine abuse: a variant of the neuroleptic malignant syndrome? Daras M; Kakkouras L; Tuchman AJ; Koppel BS Acta Neurol Scand; 1995 Aug; 92(2):161-5. PubMed ID: 7484066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]